Objetivo Ananda Pharma GmbH qualified a plant derived active pharmaceutical ingredient (API) for specific heart diseases. In nanomolar doses the substance protects cardiomyocytes by stabilizing the Na+/K+ -ATPase. The API enables ischemic preconditioning and has a balancing effect on the energy metabolism of cardiomyocytes by enhancing the turnover of lactate to ATP. The specific mode of action conveys a larger therapeutic range which means a smaller risk for unwanted side effects compared to similar substances.The API targets mainly on the small vessels and the myocardial cell, rather than on the large vessels, and therefore can be useful to distinguish between relevant obstructive coronary atherosclerosis and the actual ischemia in the microvasculature or in the myocardial cell itself. These properties convey the great potential as a new diagnostic medical device for patients with angina pectoris due to ischemic heart conditions. Therefore Ananda Pharma GmbH developed AnandaCor®, an innovative tablet formulation of the active pharmaceutical ingredient.Since cardiovascular and ischemic heart conditions are highly prevalent in all industrialized countries, with over 2 million deaths per year and estimated external costs of nearly 110 billion € per annum in the European Union alone, there is an urgent need for effective diagnostic investigation. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2015 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador ANANDA PHARMA GMBH Aportación neta de la UEn € 50 000,00 Dirección KARL LIEBKNECHT STRASSE 94 14482 POTSDAM Alemania Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Brandenburg Brandenburg Potsdam Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
